Date published: 2026-3-20

1-800-457-3801

SCBT Portrait Logo
Seach Input

MLL2 Inhibitors

MLL2 inhibitors comprise a diverse range of compounds primarily known for their ability to modulate key cellular processes such as histone modification, DNA methylation, and chromatin remodeling. These inhibitors do not directly target MLL2 but influence the cellular environment and signaling networks that regulate MLL2's activity or expression. The primary mechanism of action for these inhibitors involves the alteration of epigenetic regulation and chromatin state, which indirectly affect the functionality of MLL2. Compounds such as 3-Deazaneplanocin A, Disulfiram, Vorinostat, and Panobinostat target various components of the histone modification machinery, including histone deacetylases and other histone methyltransferases. By modulating these enzymes, these inhibitors can indirectly impact MLL2's role in histone methylation. This is particularly relevant since histone acetylation and methylation are often interrelated and cooperatively regulate gene expression. Another aspect of these inhibitors is their impact on DNA methylation and the overall epigenetic landscape. Agents such as Decitabine and 5-Azacytidine, which alter DNA methylation patterns, can indirectly influence MLL2 by modifying the transcriptional landscape in which MLL2 operates. Additionally, compounds like Temozolomide, which affects DNA repair mechanisms, and C646, a histone acetyltransferase inhibitor, can have indirect effects on MLL2 activity by altering chromatin dynamics and gene expression patterns. It is crucial to note that the effectiveness of these compounds in specifically inhibiting MLL2 depends on various factors, including the cellular context, concentration, and duration of exposure. The broader cellular effects of these compounds also need to be considered, as they influence a wide range of cellular processes and pathways. While these compounds offer insights into the regulation of MLL2 activity, their role in specifically targeting MLL2-mediated processes warrants further experimental validation in relevant biological models.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

3-Deazaneplanocin, HCl salt

120964-45-6sc-351856
sc-351856A
sc-351856B
1 mg
5 mg
10 mg
$256.00
$612.00
$936.00
2
(1)

DZNep is an inhibitor of EZH2, a component of the Polycomb Repressive Complex 2 (PRC2), which is involved in histone methylation. By inhibiting EZH2, DZNep may indirectly affect MLL2, as both are involved in histone methylation processes.

Disulfiram

97-77-8sc-205654
sc-205654A
50 g
100 g
$53.00
$89.00
7
(1)

Disulfiram, studied in the research of alcohol dependence, can also inhibit histone deacetylases (HDACs). By affecting acetylation, it could indirectly modulate MLL2's function in chromatin remodeling and gene expression.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

Suberoylanilide Hydroxamic Acid, an HDAC inhibitor, affects chromatin structure and gene expression. Its inhibition of HDACs may indirectly affect MLL2 by altering the histone acetylation status, which is interrelated with histone methylation.

Panobinostat

404950-80-7sc-208148
10 mg
$200.00
9
(1)

Panobinostat, another HDAC inhibitor, might indirectly modulate MLL2 activity by affecting the balance between histone acetylation and methylation, which are crucial for gene regulation.

Romidepsin

128517-07-7sc-364603
sc-364603A
1 mg
5 mg
$218.00
$634.00
1
(1)

Romidepsin, a cyclic peptide HDAC inhibitor, may indirectly influence MLL2 by altering histone acetylation, thereby affecting the chromatin state and potentially MLL2's role in gene expression.

GSK-J4

1373423-53-0sc-507551
100 mg
$1275.00
(0)

GSK-J4 is an inhibitor of the demethylase JMJD3. By inhibiting JMJD3, it might indirectly affect MLL2 activity, as both enzymes are involved in the regulation of histone methylation.

MS-275

209783-80-2sc-279455
sc-279455A
sc-279455B
1 mg
5 mg
25 mg
$24.00
$90.00
$212.00
24
(2)

MS-275, an HDAC inhibitor, could indirectly influence MLL2 activity through its effects on histone acetylation, impacting chromatin dynamics and gene expression.

Temozolomide

85622-93-1sc-203292
sc-203292A
25 mg
100 mg
$91.00
$255.00
32
(1)

Temozolomide, an alkylating agent used in cancer therapy, may indirectly affect MLL2 by altering DNA repair mechanisms and cellular stress responses, which can influence chromatin remodeling.

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$218.00
$322.00
$426.00
7
(1)

5-Aza-2′-Deoxycytidine, a DNA methyltransferase inhibitor, can influence gene expression patterns. Its impact on DNA methylation might indirectly affect MLL2's role in histone methylation and gene regulation.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

5-Azacytidine, another DNA methyltransferase inhibitor, may indirectly modulate MLL2 activity by influencing the overall epigenetic landscape, including histone methylation patterns.